Pharmacology News

This episode explores the alarming link between common medications and falls among older adults, revealing how psychotropics and polypharmacy contribute to up to three-quarters of incidents in nursing homes. Drawing on key studies, it details high-risk drug classes and their mechanisms while offering practical prevention strategies like medication reviews and lifestyle interventions. Essential listening for families, caregivers, and healthcare professionals seeking to safeguard elderly independence and reduce preventable injuries.

In the ER, seconds matter when identifying the "Dangerous Tetrad": rigidity, fever, autonomic instability, and altered mentation. This episode breaks down the clinical markers and pathophysiology of these life-threatening syndromes to help clinicians differentiate between NMS and Serotonin Syndrome. A must-listen for healthcare professionals looking to sharpen their diagnostic skills and improve patient outcomes in high-acuity settings.

Psychiatrists are clashing over antidepressant withdrawal: clinic data shows up to 50% of long-term SSRI/SRI users face severe symptoms, while a major 2025 JAMA Psychiatry meta-analysis claims they’re usually mild and brief. We break down both sides, expose the massive limitations in the studies, and reveal what this means for millions on these drugs.

While GLP-1 receptor agonists are not inherently "muscle-toxic," the rapid metabolic shift they induce can lead to a catabolic state that consumes lean tissue. In this episode, we dive into the pharmacology of semaglutide and tirzepatide, examining how slowed gastric emptying and blunted appetite signals impact the leucine threshold required for muscle protein synthesis. We explore the "glucose-alanine cycle," the role of myostatin inhibitors in future drug pipelines, and how adjusted protein dosing ($1.2$ to $1.6\text{ g/kg}$) can act as a pharmacological safeguard against sarcopenia.

This episode explores ibogaine as a controversial psychedelic treatment for addiction, examining its reported effects on opioid withdrawal, cravings, and psychological insight alongside serious cardiac and neurological risks. It provides a balanced, evidence-based analysis of ibogaine research, including limitations such as lack of randomized trials, selection bias, and short-term outcome data. Ideal for listeners interested in addiction science, mental health innovation, neuroscience, and the risks and promise of emerging psychedelic therapies.

Antidepressants demonstrate modest but real benefits for moderate-to-severe depression, with large meta-analyses showing consistent advantages over placebo and meaningful improvements in function for many patients, yet these gains are often smaller than portrayed and heavily influenced by high placebo responses.
The evidence base comes with important limitations, including publication bias, short trial durations, industry influence, and challenges in blinding, which can inflate perceived efficacy while understating long-term risks such as sexual dysfunction, emotional blunting, and weight gain reported more frequently in real-world surveys.
Navigating antidepressants requires pragmatic humility: they are a valuable tool for the right person at the right time when used with careful monitoring, deprescribing when appropriate, and combined with therapy and lifestyle changes, rather than as a one-size-fits-all solution or something to fear outright.